Background: Last decade, cell-derived microparticles plasma level has been used as a potential biomarker in several diseases. these particles play an important role in the patient’s clinical condition and were related to various events such as thrombosis and inflammation.

Aims: Present study assessed the platelet microparticles (PMPs) role as a biomarker of thrombotic event in Thrombotic Thrombocytopenic Purpura (TTP) patients.

Methods: This is a cross-sectional study was conducted in TTP patients refer to all hospitals at Shiraz, Iran, from Jun 2015-Jun 2019. This study was approved by medical ethics committee of Shiraz University of Medical Sciences. We evaluate TTP patients at before plasma exchange (acute phase), after plasma exchange and remission phase. Microparticles were prepared by centrifugation and the size determining of PMPs was done via ´Dynamic Light Scattering (DLS)´ Zetasizer. Platelet microparticles count, perform by Flowcytometery and for PMPs activity assay we used ZYMUPHEN MP-Activity kit. Data were analyzed by SPSS software v.21 and P-values less than 0.05 was considered statistically significant.

Results: Evaluation of PMPs level in TTP patients at 3 clinical phases revealed that PMPs count in TTP patients at before plasma exchange was higher than after plasma exchange and remission phase (P-value< 0.001) and also higher than normal healthy individuals (chart1), furthermore PMPs activity assay showed that PMPs activity in TTP patients was higher than normal individuals (table 1).

Conclusions: It seem that elevated PMPs in TTP patients could be related to patient’s condition and thrombotic events, then PMPs level in TTP patients could be apply as a prognostic biomarker of patient’s thrombosis. Nevertheless, more studies are needed to confirm these results.

« Back to ISTH 2020 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/plasma-platelets-microparticles-as-a-biomarker-of-thrombotic-event-in-thrombotic-thrombocytopenic-purpura-patients/